Professor Ruth Clifford
Professor Ruth Clifford, a Consultant Haematologist at UHL since November 2016, stands at the forefront of malignant haematology, specializing in the treatment of lymphoid malignancies, including chronic lymphocytic leukaemia (CLL). Her journey in medicine began with a medical degree from NUI Galway in 2002, leading to specialist haematology training in Ireland and later in Oxford.
Prof. Clifford's expertise shines in her research, which delves into the genetic underpinnings of blood cancers and the challenging issue of relapse and resistant disease. A notable milestone in her career was the Cancer Research UK Fellowship, which funded her PhD at the University of Oxford. Her doctoral work, exploring Next Generation Sequencing Technologies in Leukaemia, led to the significant discovery of a novel SAMHD1 gene mutation, a key to understanding chemotherapy resistance in CLL.
Her contributions to the field of haematology are widespread, with publications in collaboration with various UK and European CLL groups. Prof. Clifford maintains a robust presence in haematology genomics research, ensuring her work remains at the cutting edge of medical science.
In addition to her research, Prof. Clifford plays an integral role in clinical trial networks. She serves as the translational co-chair of the Haematology and Lymphoma DSSG of Cancer Trials Ireland and is an Investigator with the Blood Cancer Network Ireland. Her membership in the molecular advisory group for the National Cancer Control Programme highlights her influence in developing national infrastructure for partner diagnostics in Haemato-Oncology.
At the University of Limerick (UL), she is a pillar lead for the Basic Sciences Pillar of ULCan and a member of the Limerick DCRC Development Committee. Her collaborative projects across ULCan pillars exemplify her dedication to bridging research and clinical practice, especially in cancer research for the benefit of the Mid West and the broader cancer community.
Professor Ruth Clifford's career is a testament to her commitment to advancing our understanding of blood cancers and improving patient outcomes through innovative research and collaborative efforts.